Recently, a phase III trial testing the NKG2A inhibitor, Monalizumab, in combination with the epidermal growth factor (EGFR) inhibitor, cetuximab, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck was discontinued as it did not meet the pre-defined efficacy criteria (NCT04590963) [56]. This evidence concerns the gene EGF and metastatic squamous cell carcinoma.